Boyer, S.
Nishimwe, M. L. http://orcid.org/0000-0003-4161-6285
Sagaon-Teyssier, L.
March, L.
Koulla-Shiro, S.
Bousmah, M.-Q.
Toby, R.
Mpoudi-Etame, M. P.
Ngom Gueye, N. F.
Sawadogo, A.
Kouanfack, C.
Ciaffi, L.
Spire, B.
Delaporte, E.
Delaporte, E.
Koulla-Shiro, S.
Ndour, C. T.
Sawadogo, A.
Le Moing, V.
Reynes, J.
Calmy, A.
Ciaffi, L.
Girard, P. M.
Eholie, S.
Chaix, M. L.
Kouanfack, C.
Tita, I.
Bazin, B.
Garcia, P.
Guiard-Schmid, J. B.
Izard, S.
Eymard-Duvernay, S.
Peeters, M.
Serrano, L.
Cournil, A.
Diallo, I.
Mben, J. M.
Toby, R.
Manga, N.
Ayangma, L.
Taman, B.
Kabore, F. N.
Kamboule, E.
Zoungrana, J.
Diouf, A.
Diallo, M.
Fortes, L.
Ngom Gueye, N. F.
Batista, G.
Aghokeng, A.
Guichet, E.
Abessolo, H.
Essomba, C.
Manirakiza, G.
Essomba, F.
Mbarga, T.
Epanda, S.
Bikie, A.
Nke, T.
Massaha, N.
Nke, E.
Ngolle, M.
Bikobo, D.
Abologo, L.
Elat, O.
Laborde-Balen, G.
Diop, A.
Diouf, B.
Bara, N.
Koita Fall, M. B.
Toure Kane, C.
Seck, F. B.
Ba, S.
Njantou, P.
Ndyaye, A.
Hema, A.
Fao, P.
Ouedrago, P.
Traore, R.
Sanou, Y.
Bado, G.
Coulibaly, M.
Some, E.
Some, J.
Kambou, A.
Tapsoba, A.
Sombie, D.
Sanou, S.
Traore, B.
Flandre, P.
Michon, C.
Drabo, J.
Simon, F.
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa
https://doi.org/10.1007/s41669-019-0157-9
Funding for this research was provided by:
Agence Nationale de Recherche sur le Sida et les Hépatites Virales (12169, 12231)
European and Developing Countries Clinical Trials Partnership (IP.2007.33011.004)
Article History
First Online: 4 July 2019
Compliance with Ethical Standards
:
: The participating countries’ national Ethic Committees approved the protocol for the economic evaluation study and the protocol of the trial. In addition, the trial protocol was approved by the institutional Ethics Committee of the Institut de Recherche pour le Développement (IRD) in France. All participants provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guidelines. The trial is registered with ClinicalTrial.gov with the number NCT00928187.
: L.C, S.K-S and A.S report grants from ANRS with financial support by Janssen Pharmaceuticals. E.D, C.K, R.T, N.F.N.G, S.B, L.M, M.L.N, L.S-T, M.A.B, M.P.M-E and B.S report no conflict of interest in relation to this study.
: This work was supported by the Agence National de Recherche sur le SIDA—Inserm ANRS (Grant number 12231). The trial was sponsored by Agence National de Recherche sur le SIDA—Inserm ANRS (Grant number 12169) and by European and Developing Countries Clinical Trials Partnership (EDCTP) (Grant number IP.2007.33011.004). Gilead Sciences and Janssen provided study drugs, the latter partially funding the study. Neither firm had any role in the study design, data collection, data analysis, data interpretation or writing of the report.